{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:50:07Z","timestamp":1753876207933,"version":"3.41.2"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Recently, neoadjuvant chemotherapy comprising docetaxel, cisplatin, and 5-fluorouracil showed promising efficacy for esophageal squamous cell carcinoma. However, some patients do not achieve curative resection despite neoadjuvant chemotherapy using these drugs. This study aimed to clarify the pretherapeutic characteristics of these patients. We included 113 patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for potentially resectable esophageal squamous cell carcinoma and compared the clinical characteristics between patients who achieved curative resection (curative group) and those who failed to achieve curative resection after planned neoadjuvant chemotherapy (noncurative group). Moreover, we determined the factors predicting noncurative outcomes. Ninety-one (81%) and 22 patients (19%) were in the curative and noncurative groups, respectively. The noncurative group had significantly more tumors located in the upper third of the esophagus, larger-sized tumors, and borderline resectable tumors than the curative group (P\u2009=\u20090.003, 0.049, and &amp;lt;0.001, respectively). Moreover, the noncurative group had significantly higher serum squamous cell carcinoma antigen concentrations than the curative group (P\u2009=\u20090.008). Multivariable analysis identified tumor location in the upper third of the esophagus (odds ratio 7.31, P\u2009=\u20090.002), tumor size \u226550\u00a0mm (odds ratio 4.71, P\u2009=\u20090.037), and borderline resectable tumors (odds ratio 6.65, P\u2009=\u20090.003) as independent predictors for noncurative outcomes. Tumor location in the upper third of the esophagus, larger-sized tumors, and borderline resectable tumors might be significant predictors for noncurative outcomes in patients who received neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.<\/jats:p>","DOI":"10.1093\/dote\/doae115","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:43:17Z","timestamp":1734594197000},"source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors for failure of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy in esophageal squamous cell carcinoma"],"prefix":"10.1093","volume":"38","author":[{"given":"Masayoshi","family":"Terayama","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3217-8888","authenticated-orcid":false,"given":"Akihiko","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kanamori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Udagawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Shimozaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"3","key":"2025010911535966500_ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2025010911535966500_ref2","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1245\/s10434-020-08358-0","article-title":"Significance of neoadjuvant downstaging in carcinoma of esophagus and gastroesophageal junction","volume":"27","author":"Kamarajah","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2025010911535966500_ref3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00595-020-02059-7","article-title":"Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma","volume":"51","author":"Hiraki","year":"2021","journal-title":"Surg Today"},{"issue":"7","key":"2025010911535966500_ref4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025010911535966500_ref5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/annonc\/mdw010","article-title":"A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction","volume":"27","author":"Klevebro","year":"2016","journal-title":"Ann Oncol"},{"issue":"22","key":"2025010911535966500_ref6","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2025010911535966500_ref7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"27","key":"2025010911535966500_ref8","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025010911535966500_ref9","article-title":"Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)","volume":"42","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025010911535966500_ref10","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1200\/JCO.2003.12.095","article-title":"Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study\u2014JCOG9204","volume":"21","author":"Ando","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025010911535966500_ref11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"10447","key":"2025010911535966500_ref12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"2025010911535966500_ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox075","article-title":"Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma","volume":"30","author":"Okamura","year":"2017","journal-title":"Dis Esophagus"},{"issue":"2","key":"2025010911535966500_ref14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice","volume":"6","author":"Rice","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"issue":"3","key":"2025010911535966500_ref15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese Classification of Esophageal Cancer, 12th edition: part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus."},{"issue":"3","key":"2025010911535966500_ref16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10388-024-01048-w","article-title":"Japanese Classification of Esophageal Cancer, 12th edition: part II","volume":"21","author":"Doki","year":"2024","journal-title":"Esophagus."},{"issue":"1","key":"2025010911535966500_ref17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s002689900006","article-title":"Intramural metastases from thoracic esophageal cancer: local indicators of advanced disease","volume":"20","author":"Nishimaki","year":"1996","journal-title":"World J Surg"},{"issue":"3","key":"2025010911535966500_ref18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"issue":"1","key":"2025010911535966500_ref19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"3","key":"2025010911535966500_ref20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2025010911535966500_ref21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00268-016-3649-0","article-title":"The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) in esophageal squamous cell carcinoma","volume":"41","author":"Hiyoshi","year":"2017","journal-title":"World J Surg"},{"issue":"4","key":"2025010911535966500_ref22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/SLA.0000000000003975","article-title":"RAD51 expression as a biomarker to predict efficacy of preoperative therapy and survival for esophageal squamous cell carcinoma: a large-cohort observational study (KSCC1307)","volume":"275","author":"Saeki","year":"2022","journal-title":"Ann Surg"},{"issue":"13","key":"2025010911535966500_ref23","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1245\/s10434-019-07744-7","article-title":"Dysphagia score as a predictor of adverse events due to triplet chemotherapy and oncological outcomes in 434 consecutive patients with esophageal cancer","volume":"26","author":"Hagi","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2025010911535966500_ref24","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1245\/s10434-007-9405-9","article-title":"Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?","volume":"14","author":"Piessen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"2025010911535966500_ref25","first-page":"5","article-title":"Serum squamous cell carcinoma antigen is a predictive factor of outcomes in patients with locally advanced unresectable esophageal squamous cell carcinoma treated by definitive chemoradiotherapy","volume":"8","author":"Suzuki","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"issue":"32","key":"2025010911535966500_ref26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021470","article-title":"Heterogeneity of T3 stage esophageal squamous cell carcinoma in different parts based on enhanced CT radiomics","volume":"99","author":"Li","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2025010911535966500_ref27","first-page":"163","article-title":"Microbiome changes in esophageal cancer: implications for pathogenesis and prognosis","volume":"21","author":"Li","year":"2023","journal-title":"Cancer Biol Med"},{"issue":"8","key":"2025010911535966500_ref28","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00268-022-06568-z","article-title":"Evaluation of neoadjuvant chemoradiotherapy followed by surgery for borderline resectable esophageal squamous cell carcinoma","volume":"46","author":"Hirohata","year":"2022","journal-title":"World J Surg"},{"issue":"2","key":"2025010911535966500_ref29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1245\/s10434-020-08716-y","article-title":"Clinical significance of pretherapeutic serum squamous cell carcinoma antigen level in patients with neoadjuvant chemotherapy for esophageal squamous cell carcinoma","volume":"28","author":"Okamura","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2025010911535966500_ref30","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1245\/s10434-021-09945-5","article-title":"Clinical significance of serum squamous cell carcinoma antigen for patients with recurrent esophageal squamous cell carcinoma","volume":"28","author":"Kanie","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2025010911535966500_ref31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025010911535966500_ref32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejca.2010.09.009","article-title":"Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial","volume":"47","author":"Burmeister","year":"2011","journal-title":"Eur J Cancer"},{"issue":"9","key":"2025010911535966500_ref33","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1245\/s10434-023-13686-y","article-title":"Neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy for patients with esophageal squamous cell carcinoma: real-world data comparison from a Japanese nationwide study","volume":"30","author":"Okamura","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2025010911535966500_ref34","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1245\/s10434-022-12960-9","article-title":"Development and validation of a predictive model of therapeutic effect in patients with esophageal squamous cell carcinoma who received neoadjuvant treatment: a nationwide retrospective study in Japan","volume":"30","author":"Okamura","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2025010911535966500_ref35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10388-019-00709-5","article-title":"Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer","volume":"17","author":"Hashimoto","year":"2020","journal-title":"Esophagus"},{"issue":"4","key":"2025010911535966500_ref36","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.21873\/anticanres.14986","article-title":"Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) vs. cisplatin and 5-fluorouracil (CF-RT) for patients with unresectable locally advanced esophageal cancer in a real-world clinical setting","volume":"41","author":"Sakai","year":"2021","journal-title":"Anticancer Res"},{"issue":"10","key":"2025010911535966500_ref37","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.21873\/anticanres.15999","article-title":"Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for patients with potentially resectable esophageal cancer","volume":"42","author":"Sakai","year":"2022","journal-title":"Anticancer Res"},{"issue":"7","key":"2025010911535966500_ref38","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.21873\/anticanres.15862","article-title":"Strategy treatment of ct4b esophageal squamous cell carcinoma using docetaxel, cisplatin, and 5-fluorouracil","volume":"42","author":"Nakajima","year":"2022","journal-title":"Anticancer Res"},{"issue":"2","key":"2025010911535966500_ref39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.31557\/APJCP.2022.23.2.495","article-title":"Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced cervical esophageal cancer: a medium-term outcome","volume":"23","author":"Okamoto","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"2025010911535966500_ref40","article-title":"FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)\u2014short-term results for cohorts C and D","volume":"40","author":"Matsuda","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025010911535966500_ref41","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s10388-021-00826-0","article-title":"Performance of a deep learning-based identification system for esophageal cancer from CT images","volume":"18","author":"Takeuchi","year":"2021","journal-title":"Esophagus"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/1\/doae115\/61233044\/doae115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/1\/doae115\/61233044\/doae115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:54:25Z","timestamp":1736423665000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doae115\/7928276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doae115","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"type":"print","value":"1120-8694"},{"type":"electronic","value":"1442-2050"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,19]]},"article-number":"doae115"}}